Potential therapeutic targets for NASH, as available from phase 2 and 3 clinical trials. Sites of action include liver pathways involved in lipid and glucose homeostasis, oxidative stress, mitochondrial function, inflammatory signals, intracellular targets related to stellate cell activation and fibrogenesis. Some targets (e.g., FXR agonists, C-C motif chemokine receptor [CCR] 2 and 5 (CCR2/5) antagonist) display more than one action site. Additional extrahepatic interventions appear in the left lower box. Symbols point to agonists (+) or antagonist (-) effect. Abbreviations: DGAT, diacylglycerol O-acyltransferase; SCD, steroyl CoA-desaturase; THR, thyroid hormone receptor; SIRT, sirtuin; GLP, glucagon-like peptide; SGLT, sodium-glucose cotransporter; VAP, vascular adhesion protein; LPS, lipopolysaccharide; PPARα/δ/γ, peroxisome proliferator-activated receptors PPARα, PPARδ and PPARγ [66].